Latest Capecitabine Stories
CHICAGO and SAN FRANCISCO, June 4, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and third-line treatment in patients with metastatic breast cancer during the 2011 American Society of Clinical Oncology Meeting (ASCO).
WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.
WAYNE, N.J. and SOUTH SAN FRANCISCO, May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.
BARCELONA, April 20, 2011 /PRNewswire/ -- - Advancell has announced the initiation of a clinical phase IIb study of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side effect of chemotherapy.
WAYNE, N.J. and EMERYVILLE, Calif., Feb. 24, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb.
SAN ANTONIO, and SAN FRANCISCO, Dec.
THE WOODLANDS, Texas, Dec.
THE WOODLANDS, Texas, Dec. 8, 2010 /PRNewswire/ -- World-class investigators affiliated with US Oncology Research participated in studies that will be presented, discussed and displayed Dec.
SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ -- The U.S.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.